Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of alemtuzumab in German patients with Multiple Sclerosis

Next Previous
Trial Profile

Effect of alemtuzumab in German patients with Multiple Sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms TREAT-MS

Most Recent Events

  • 26 Apr 2022 Interim Results (cut-off 02 FEB 2021, n=494 ) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 15 Oct 2021 Interim results (as of Feb 2021; n=907) presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 01 May 2020 Interim results (as of October 2018; n=778) of sub-group analysis by timing of initiation assessing efficacy of alemtuzumab in RRMS patients, presented at the 72nd Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top